<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="35219"><DrugName>perflexane-lipid microsphere</DrugName><DrugNamesKey><Name id="42799480">Imagent</Name><Name id="42799483">Imagent US</Name><Name id="42799481">Imavist</Name><Name id="42819786">perflexane</Name></DrugNamesKey><DrugSynonyms><Name><Value>Imagent</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Imavist</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>ZK-194228</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Imagent US</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>SH-U-666-A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>perflexane air bubble suspension, Alliance/Schering AG</Value></Name><Name><Value>perfluorochemical microbubbles (ultrasound contrast agent), Alliance/Schering AG</Value></Name><Name><Value>perflexane-containing air bubbles (ultrasound contrast agent), IMCOR</Value></Name><Name><Value>perflexane-lipid microsphere</Value></Name><Name><Value>perflexane</Value><Types><Type>INN</Type></Types></Name><Name><Value>AF-0150</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>355-42-0</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14053">New Alliance Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="17722">Kyosei Seiyaku Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="14053">New Alliance Pharmaceuticals Inc</Company><Company id="16827">IMCOR Pharmaceutical Co</Company><Company id="19687">Bayer Schering Pharma AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="35219" type="Drug"><TargetEntity id="228512" type="siDrug">Perflexane lipid microspheres</TargetEntity></SourceEntity><SourceEntity id="14053" type="Company"><TargetEntity id="4295905477" type="organizationId">Alliance Pharmaceutical Corp</TargetEntity></SourceEntity><SourceEntity id="16827" type="Company"><TargetEntity id="4295914548" type="organizationId">IMCOR Pharmaceutical Co</TargetEntity></SourceEntity><SourceEntity id="17722" type="Company"><TargetEntity id="4297831593" type="organizationId">Kyosei Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="19687" type="Company"><TargetEntity id="4295869029" type="organizationId">Bayer Pharma AG</TargetEntity></SourceEntity><SourceEntity id="276" type="ciIndication"><TargetEntity id="C61" type="ICD10"></TargetEntity><TargetEntity id="10060862" type="MEDDRA"></TargetEntity><TargetEntity id="D011471" type="MeSH"></TargetEntity><TargetEntity id="-405461207" type="omicsDisease"></TargetEntity><TargetEntity id="637" type="siCondition"></TargetEntity><TargetEntity id="5083" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"></TargetEntity><TargetEntity id="D002318" type="MeSH"></TargetEntity><TargetEntity id="-1500764314" type="omicsDisease"></TargetEntity><TargetEntity id="182" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Cardiovascular disease - US - Jun-2002</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="57">Cardiovascular disease</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="276">Prostate tumor</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsSecondary><Action id="7220">Neoplasm diagnostic agent</Action><Action id="7210">Cardiovascular diagnostic agent</Action><Action id="4156">Ultrasound contrast agent</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="731">Imaging</Technology></Technologies><EphmraCodes><Ephmra><Code>C</Code><Name>CARDIOVASCULAR SYSTEM</Name></Ephmra><Ephmra><Code>T1F</Code><Name>ULTRASOUND AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-06-11T06:56:10.000Z</LastModificationDate><ChangeDateLast>2018-06-11T00:00:00.000Z</ChangeDateLast><AddedDate>2001-07-19T10:07:11.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="16827" linkType="Company"&gt;IMCOR Pharmaceutical&lt;/ulink&gt; (previously Photogen Technologies) was marketing Imagent (ZK-194228; SH-U-666-A; Imagent US; formerly Imavist), perflexane lipid microspheres, as an iv ultrasound contrast agent to visualize heart structure [&lt;ulink linkID="453364" linkType="reference"&gt;453364&lt;/ulink&gt;], [&lt;ulink linkID="494124" linkType="Reference"&gt;494124&lt;/ulink&gt;]. It is also developing the agent for other indications (in collaboration with &lt;ulink linkID="17722" linkType="Company"&gt;Kyosei&lt;/ulink&gt; in Japan), including myocardial perfusion imaging and radiology applications  [&lt;ulink linkID="517370" linkType="reference"&gt;517370&lt;/ulink&gt;], [&lt;ulink linkID="574869" linkType="Reference"&gt;574869&lt;/ulink&gt;]. The product was approved by the FDA in June 2002  to  visualize the left ventricle and to improve delineation of the endocardial borders of the heart [&lt;ulink linkID="453364" linkType="reference"&gt;453364&lt;/ulink&gt;] and launched in the US by &lt;ulink linkID="14053" linkType="Company"&gt;New Alliance Pharmaceuticals&lt;/ulink&gt;, previously   Alliance Pharmaceutical, later that month [&lt;ulink linkID="454641" linkType="Reference"&gt;454641&lt;/ulink&gt;], [&lt;ulink linkID="462683" linkType="Reference"&gt;462683&lt;/ulink&gt;]. By October 2013, the drug was withdrawn from the US market [&lt;ulink linkID="1484863" linkType="Reference"&gt;1484863&lt;/ulink&gt;]. In December 2004, IMCOR initiated a phase II trial of  the agent (using higher doses of Imagent) to image myocardial perfusion for the detection of coronary artery disease; at this time other indications requiring higher doses of Imagent were also under development, including radiology applications  [&lt;ulink linkID="574869" linkType="Reference"&gt;574869&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="14053" linkType="Company"&gt;Alliance&lt;/ulink&gt; developed and launched Imagent for its initial indication, and continued to develop the agent until June 2003, when Photogen Technologies (now IMCOR Pharmaceutical) purchased Alliance's rights to the compound [&lt;ulink linkID="494124" linkType="reference"&gt;494124&lt;/ulink&gt;], [&lt;ulink linkID="514779" linkType="reference"&gt;514779&lt;/ulink&gt;]. &lt;ulink linkID="19687" linkType="Company"&gt;Schering AG&lt;/ulink&gt; had been codeveloping the agent with Alliance. In November 2000, Schering was preparing to submit an MAA during the first half of 2001 [&lt;ulink linkID="389163" linkType="reference"&gt;389163&lt;/ulink&gt;]; in July 2001, Schering gave the estimated filing date in the EU as 2002 [&lt;ulink linkID="416493" linkType="reference"&gt;416493&lt;/ulink&gt;]. However, no further European development was  reported and, in March 2002, Alliance regained from Schering exclusive US marketing rights for cardiology indications for 5 years [&lt;ulink linkID="441855" linkType="reference"&gt;441855&lt;/ulink&gt;] and no further development has been reported by Schering since.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;An NDA was filed for Imagent with the FDA in October 1999 [&lt;ulink linkID="324283" linkType="reference"&gt;324283&lt;/ulink&gt;], [&lt;ulink linkID="344741" linkType="reference"&gt;344741&lt;/ulink&gt;]. In December 1999, Alliance announced that an NDA had been accepted by the FDA, and in August 2000, Alliance received an approvable notification from the FDA [&lt;ulink linkID="379768" linkType="reference"&gt;379768&lt;/ulink&gt;]. The NDA included clinical data from two phase III studies which demonstrated that use of the agent provided a highly significant improvement in endocardial border delineation compared to standard ultrasound imaging [&lt;ulink linkID="350613" linkType="reference"&gt;350613&lt;/ulink&gt;]. Following an approvable notification from the FDA in August 2000, for use of the agent in endocardial border delineation [&lt;ulink linkID="379768" linkType="reference"&gt;379768&lt;/ulink&gt;], Alliance submitted additional documentation to the FDA in August 2001; at this time, the company hoped to receive approval later in 2001 [&lt;ulink linkID="419880" linkType="reference"&gt;419880&lt;/ulink&gt;], [&lt;ulink linkID="427568" linkType="reference"&gt;427568&lt;/ulink&gt;]. In November 2001, following a successful pre-approval inspection of its manufacturing facility, Alliance received a letter stating that the FDA was recommending approval for Imagent [&lt;ulink linkID="431422" linkType="reference"&gt;431422&lt;/ulink&gt;]. By March 2002, the FDA had reviewed Alliance's NDA and found it to be approvable upon submission of additional information related primarily to product labeling [&lt;ulink linkID="441855" linkType="reference"&gt;441855&lt;/ulink&gt;], [&lt;ulink linkID="441856" linkType="reference"&gt;441856&lt;/ulink&gt;]. The FDA approved Imagent,  for use in patients with suboptimal echocardiograms to opacify the left ventricle and thereby improve its visualization, and to improve delineation of the endocardial borders of the heart, in June 2002 [&lt;ulink linkID="453364" linkType="reference"&gt;453364&lt;/ulink&gt;]. By October 2013, the drug was withdrawn from the US market [&lt;ulink linkID="1484863" linkType="Reference"&gt;1484863&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;ENDOCARDIAL BORDER DELINEATION&lt;/subtitle&gt;In May 1999, phase III studies of the agent were completed. These involved approximately 500 patients, and demonstrated improved echocardiographic evaluation of the heart compared to standard (non-contrasted) ultrasound imaging. At this time, the company had expected to receive approval for the product during the first half of 2001. In June 2002, Alliance presented phase III data for Imagent at the American Society of Echocardiography 13th Annual Scientific Sessions in Orlando, FL. The program, involved two prospective, randomized, controlled studies and included 409 patients with suboptimal baseline images using fundamental ultrasound imaging. Six independent blinded readers reviewed unpaired non-contrast and contrast exams and scored endocardial border delineation (EBD) in 16 cardiac segments using standardized criteria. All six readers recorded significant improvement in total EBD scores with the use of Imagent. These results were verified in a subset of patients through a separate assessment of segmental wall motion by an independent imaging technique, MRI, which demonstrated an increased ability to assess normal versus abnormal wall motion [&lt;ulink linkID="454641" linkType="reference"&gt;454641&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 1998, phase II studies of Imagent for the assessment of cardiprostatac function and detection of myocardial infarction had been completed and phase III studies had commenced [&lt;ulink linkID="264163" linkType="reference"&gt;264163&lt;/ulink&gt;], [&lt;ulink linkID="282797" linkType="reference"&gt;282797&lt;/ulink&gt;]. The agent was well tolerated in phase I trials and showed gray-scale ultrasound contrast enhancement of cardiac, abdominal and vascular structures at all doses. In preclinical studies, the product enhanced the signal from perfused tissues and blood vessels using traditional gray-scale and color Doppler ultrasonography, as well as emerging harmonic imaging technique [&lt;ulink linkID="221620" linkType="reference"&gt;221620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;MYOCARDIAL PERFUSION&lt;/subtitle&gt;In December 2004, IMCOR initiated a phase II trial of the agent to image myocardial perfusion for the detection of coronary artery disease. The trial, one of a series of studies to investigate the safety and efficacy of higher doses of the agent, would assess alternative administration methods, including repeat dosing and infusion. Preliminary studies carried out by this time, using the phasic changes imaging method, had showed encouraging results [&lt;ulink linkID="574869" linkType="Reference"&gt;574869&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PROSTATE CANCER&lt;/subtitle&gt;In October 2001, Alliance reported that a landmark clinical study was to take place at &lt;ulink linkID="20685" linkType="Company"&gt;Thomas Jefferson University&lt;/ulink&gt; Hospital, Philadelphia using Imagent with ultrasound imaging to improve detection of prostate cancer. The study was to be a non-randomized trial in which all patients were to receive an iv infusion of Imagent to achieve prolonged contrast enhancement of the prostate. By March 2002, this study was underway and had enrolled 300 men with suspected prostate cancer [&lt;ulink linkID="424652" linkType="reference"&gt;424652&lt;/ulink&gt;], [&lt;ulink linkID="441855" linkType="reference"&gt;441855&lt;/ulink&gt;]. In November 2004,  results were presented at the Radiological Society of North America meeting in Chicago, IL. Imagent increased cancer detection rate, compared to a standard sextant approach and also demonstrated an improvement in discrimination between benign and malignant areas within the prostate outer gland. In a separate study, contrast enhanced ultrasound imaging using Imagent in 29 patients to determine residual blood flow in tumors following chemoembolization, showed that the outcome  was predictable 1 week following Imagent treatment, compared to 3 months following computed tomography or magnetic resonance imaging. A further study showed that Imagent allowed visualization of tumor blood flow in response to antiangiogenesis treatment in VX-2 tumors in rabbits injected with the angiogenesis inhibitor, &lt;ulink linkID="2441" linkType="Drug"&gt;TNP-470&lt;/ulink&gt; [&lt;ulink linkID="573128" linkType="Reference"&gt;573128&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Imagent is a second-generation perfluorochemical-based ultrasound agent: Alliance's Imagent GI was approved by the FDA for oral gastrointestinal MRI imaging in August 1993; however, due to high manufacturing and selling costs, the compound was discontinued in November 1994 [&lt;ulink linkID="196932" linkType="reference"&gt;196932&lt;/ulink&gt;]. In 1994, Imagent LN (lymph nodes) and Imagent BP (blood pool) were also discontinued, having reached phase I clinical trials [&lt;ulink linkID="181778" linkType="reference"&gt;181778&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2002, Alliance and Photogen (now IMCOR) executed a term sheet for Photogen to acquire all of the assets of Alliance related to medical imaging, including all manufacturing and marketing rights to Imagent. The transaction was subject to completion of due diligence, negotiation of definitive agreements and other contingencies, including Photogen obtaining financing for the acquisition. Under certain circumstances, if the acquisition did not occur, Alliance would be required to pay a break-up fee to Photogen. The financing structure contemplated by the term sheet included Photogen providing to Alliance a cash payment at closing, future payments based on product sales, and bridge financing for Imagent activities prior to the acquisition [&lt;ulink linkID="471705" linkType="reference"&gt;471705&lt;/ulink&gt;], [&lt;ulink linkID="471706" linkType="reference"&gt;471706&lt;/ulink&gt;]. In June 2003, Alliance completed the sale [&lt;ulink linkID="494124" linkType="reference"&gt;494124&lt;/ulink&gt;]. In September 2005, IMCOR and Alliance reached an agreement freeing them of their obligations under the previous asset purchase agreement [&lt;ulink linkID="624741" linkType="Reference"&gt;624741&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2003, Photogen licensed the Japanese development and marketing rights for Imagent to &lt;ulink linkID="17722" linkType="Company"&gt;Kyosei Seiyaku Co Ltd&lt;/ulink&gt; to develop Imagent for radiology and cardiology indications in Japan [&lt;ulink linkID="517370" linkType="reference"&gt;517370&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 1997, Alliance and Schering signed an agreement under which the agent was to be developed jointly by Schering and Alliance, and marketed exclusively by Schering [&lt;ulink linkID="264163" linkType="reference"&gt;264163&lt;/ulink&gt;]. In March 2002, Alliance and Schering modified their partnership whereby Alliance was to increase its participation in the marketing of Imagent. Also at this time, Alliance entered into a 5-year exclusive agreement with Cardinal Health to assist in the marketing of Imavist. Under the agreement, Cardinal Health would perform certain packaging, distribution, and sales services for Alliance under a fee-for-service arrangement [&lt;ulink linkID="441855" linkType="reference"&gt;441855&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, the USPTO issued a patent, 'Mixed Gas Microbubble Composition', covering the formation of stabilized microbubble formulations, including Imagent [&lt;ulink linkID="594384" linkType="Reference"&gt;594384&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 1997, Alliance was issued US-05605673, entitled, 'Stabilized microbubble compositions for ultrasound'. The patent covers methods of forming stable microbubble formulations including Imagent [&lt;ulink linkID="235785" linkType="reference"&gt;235785&lt;/ulink&gt;]. In April 1998, Alliance was issued with US-05733527, which broadly covers methods of harmonic imaging using second-generation contrast agents such as Imagent [&lt;ulink linkID="283463" linkType="reference"&gt;283463&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17722">Kyosei Seiyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-12-19T00:00:00.000Z</StatusDate><Source id="517370" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16827">IMCOR Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-10-07T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19687">Bayer Schering Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-03-01T00:00:00.000Z</StatusDate><Source id="441855" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19687">Bayer Schering Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-09T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19687">Bayer Schering Pharma AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-09T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14053">New Alliance Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-06-19T00:00:00.000Z</StatusDate><Source id="494124" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14053">New Alliance Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-06-19T00:00:00.000Z</StatusDate><Source id="494124" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="16827">IMCOR Pharmaceutical Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-06-19T00:00:00.000Z</StatusDate><Source id="494124" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14053">New Alliance Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-03-04T00:00:00.000Z</StatusDate><Source id="441855" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14053">New Alliance Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-06-04T00:00:00.000Z</StatusDate><Source id="453364" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14053">New Alliance Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-07-19T00:00:00.000Z</StatusDate><Source id="416181" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14053">New Alliance Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-11-01T00:00:00.000Z</StatusDate><Source id="344741" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19687">Bayer Schering Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-02-01T00:00:00.000Z</StatusDate><Source id="316157" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19687">Bayer Schering Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-10-01T00:00:00.000Z</StatusDate><Source id="264163" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14053">New Alliance Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-04-01T00:00:00.000Z</StatusDate><Source id="282797" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14053">New Alliance Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-11-01T00:00:00.000Z</StatusDate><Source id="221620" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14053">New Alliance Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1995-03-01T00:00:00.000Z</StatusDate><Source id="181778" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19687">Bayer Schering Pharma AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-11-09T00:00:00.000Z</StatusDate><Source id="389163" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19687">Bayer Schering Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-11-01T00:00:00.000Z</StatusDate><Source id="344741" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19687">Bayer Schering Pharma AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-02-01T00:00:00.000Z</StatusDate><Source id="316157" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14053">New Alliance Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2002-06-12T00:00:00.000Z</StatusDate><Source id="454641" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14053">New Alliance Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="14455">Bayer AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16827">IMCOR Pharmaceutical Co</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="27801">Sakai Chemical Industry Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="17">Patent - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C(C(C(C(F)(F)F)(F)F)(F)F)(C(C(F)(F)F)(F)F)(F)F</Smiles></StructureSmiles><Deals><Deal id="123313" title="Kyosei Seiyaku to develop Photogen's Imagent in Japan for cardiovascular disease "></Deal><Deal id="123316" title="Alliance and Schering jointly develop Imagent worldwide"></Deal><Deal id="123317" title="Photogen acquires Alliance's assets related to medical imaging, including rights to Imagent"></Deal></Deals><PatentFamilies><PatentFamily id="115593" number="WO-09503835" title="Stabilized Microbubble Compositions For Ultrasound"></PatentFamily><PatentFamily id="1311300" number="WO-09626746" title="Stabilized Gas Emulsion Containing Phospholipid For Ultrasound Contrast Enhancement"></PatentFamily><PatentFamily id="2053575" number="WO-09609793" title="Harmonic Ultrasound Imaging With Microbubbles"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lantheus Medical Imaging Inc" id="1004416"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="New Alliance Pharmaceuticals Inc" id="14053"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="IMCOR Pharmaceutical Co" id="16827"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="General Electric Co" id="CM27927"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>